Innovative Blood Test Offers New Hope in Detecting Esophageal Cancer
PromarkerEso is a groundbreaking blood-based test developed to accurately rule out esophageal adenocarcinoma, enabling earlier and less invasive detection and diagnosis of this deadly cancer.
Proteomics International has introduced PromarkerEso, a revolutionary blood-based diagnostic tool designed to identify esophageal adenocarcinoma (EAC). This groundbreaking test was unveiled at the ISDE World Congress in Brisbane and is recognized as the first of its kind to utilize protein biomarkers for ruling out esophageal cancer. Published research in the journal Proteomes supports its high accuracy and reliability.
Esophageal cancer, particularly EAC, is among the deadliest cancers worldwide. Often, early signs such as Barrett's esophagus—a condition affecting up to 2% of adults—go undetected. PromarkerEso addresses a critical gap by enabling earlier detection in primary care, which can significantly improve outcomes.
Traditionally, individuals with symptoms like chronic reflux undergo invasive endoscopy, often repeated annually or bi-annually, requiring fasting, anesthesia, and recovery time. In contrast, PromarkerEso provides a quick, non-invasive alternative through a standard blood test conducted at local collection centers, reducing patient anxiety and logistical burdens.
Validated with impressive clinical results, the test demonstrates a Negative Predictive Value of 99.99%, indicating that a negative result confidently rules out EAC, thus potentially decreasing unnecessary procedures. Its high sensitivity (91.4%) and specificity (98.9%) further empower healthcare providers to identify patients at genuine risk.
The recent shift in surveillance strategies, including questioning the routine use of bi-annual endoscopy as shown in the BOSS Trial, highlights the need for improved diagnostic tools. PromarkerEso offers a promising solution, supported by Australian health authorities and positioned at the forefront of precision medicine.
Now available across Australia, the test can be accessed via telehealth consultations and through physician referrals, with blood samples collected at a vast network of centers. As the first protein biomarker-based blood test for esophageal cancer, PromarkerEso stands to revolutionize early detection, improve patient outcomes, and reduce healthcare costs in the fight against this deadly disease.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Gwada-negative: The Rarest Blood Group on Earth
French scientists have discovered the world's rarest blood group, Gwada-negative, found in a woman from Guadeloupe. This groundbreaking finding highlights the complexity of human blood systems and the potential for future personalized transfusion solutions.
Persistent Pain After Heart Attack Linked to Increased Mortality Risk, Comparable to Smoking
New research reveals that ongoing pain a year after a heart attack can significantly increase the risk of premature death, on par with smoking and high blood pressure. The study highlights the importance of recognizing chronic pain as an independent health risk in cardiovascular care.
Childhood Central Obesity and Its Early Link to Metabolic and Heart Risks
New research reveals that increased waist-to-height ratio in children predicts early signs of metabolic and cardiovascular risks by age 10, emphasizing the importance of early detection and intervention.
Link Between Ultra-Processed Foods, Prenatal Heavy Metals, and Child Brain Development
New research explores how ultra-processed foods during pregnancy may increase heavy metal exposure in mothers, impacting child brain development and neurodevelopmental health. Nutritional interventions could play a vital role in mitigating these risks.